Novavax Received Emergency-Use Authorization

NATIONAL

  • NVX-CoV2373 (also known as Novavax), the fourth COVID Vaccine received emergency use authorization for adolescents in the age bracket of 12-18 years in India.
  • The vaccine was authorized by the Drugs Controller General of India (DCGI)
  • Novavax was manufactured by Novavax Inc. and marketed in India by the Serum Institute of India (SII) under the brand name ‘Covavax’.
  • It is the first protein-based vaccine authorized by DGCI for use in the age group 12-18 in India.
  • The vaccine proved 80% effective against COVID-19 in the age group of 12-17 years.
  • Earlier Corbevax authorized by DGCI to vaccinate children aged 12 to 14.

  Facts to know:

 

  • Other COVID vaccines for Children: Corbevax, ZyCoV-D and Covaxin.
  • Drugs Controller General of India (DGCI): Dr. V.G. Somani.
  • DGCI is the head of department of the Central Drugs Standard Control Organization (CDSCO).
 Novavax
preparing for jeet

Preparing for Govt. Exams?

Here is you path to Jeet

View courses